Minimizing predictability while retaining balance through the use of less restrictive randomization procedures.
The interpretation of between-group comparisons is facilitated by the creation of treatment groups that are similar to each other in baseline composition. To prevent treatment effects from being confounded with time effects, most trials use restricted randomization to force balance. An unintended consequence of these restrictions is that they create patterns that allow for the prediction of future treatment allocations, and hence selection bias, especially in unmasked trials. In fact, the more restrictive the allocation procedure, the greater the potential for selection bias. It was decided, in the context of a recent clinical trial comparing two dosing schedules of paclitaxel and carboplatin for advanced stage IIIB/IV non-small-cell lung cancer, that the randomized block procedure could not simultaneously protect sufficiently against both selection and chronological bias. In this paper we detail our development of the maximal procedure. The maximal procedure takes as input the extent of chronological bias allowed by the randomized block procedure, then matches it, but does so with fewer restrictions. This feature makes the maximal procedure more resistant to selection bias than the randomized block procedure is.
Berger
Vance W
VW
National Cancer Institute, EPN, Suite 3131, 6130 Executive Boulevard, MSC-7354, Bethesda, MD 20892-7354, USA. vb78c@nih.gov
Ivanova
Anastasia
A
Knoll
Maria Deloria
MD
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016190:Carboplatin / Q000008:administration & dosage; D015986:Confounding Factors, Epidemiologic; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D017239:Paclitaxel / Q000008:administration & dosage; D016032:Randomized Controlled Trials as Topic / Q000379:methods* / Q000706:statistics & numerical data*; D012107:Research Design; D015983:Selection Bias
D016190:Carboplatin; D017239:Paclitaxel